According to a recent LinkedIn post from Aignostics, company researchers Nina Kozar-Gillan, PhD, and Arne Schmidt are listed as collaborators on two oncology-focused posters at AACR 2026 led by Pfizer scientists. The posters cover spatial and transcriptomic remodeling of the tumor microenvironment in urothelial carcinoma following neoadjuvant atezolizumab, and a quantitative framework for spatial profiling of immune heterogeneity.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Aignostics is positioning its technology and expertise within high-value areas of cancer research, particularly spatial biology and immuno-oncology. For investors, this visibility at a major scientific conference and collaboration with a large pharmaceutical company could indicate validation of Aignostics’ platform and potential for future partnering or commercial opportunities in precision oncology workflows.
The mention of a dedicated Aignostics booth at AACR 2026 points to ongoing business development efforts targeting biopharma and academic stakeholders. If these interactions translate into research collaborations, software deployments, or data-analysis contracts, they could support revenue growth and strengthen Aignostics’ competitive position in the AI-powered pathology and spatial analytics segment.